• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实体瘤中免疫检查点抑制剂耐药的挑战:微生物组及其多样性能否成为我们的秘密武器?

The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?

机构信息

Department of Clinical and Molecular Medicine, Sant' Andrea University Hospital, Sapienza University of Rome, Rome, Italy.

Medical Oncology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

出版信息

Front Immunol. 2021 Aug 20;12:704942. doi: 10.3389/fimmu.2021.704942. eCollection 2021.

DOI:10.3389/fimmu.2021.704942
PMID:34489956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8417795/
Abstract

The human microbiota and its functional interaction with the human body were recently returned to the spotlight of the scientific community. In light of the extensive implementation of newer and increasingly precise genome sequencing technologies, bioinformatics, and culturomic, we now have an extraordinary ability to study the microorganisms that live within the human body. Most of the recent studies only focused on the interaction between the intestinal microbiota and one other factor. Considering the complexity of gut microbiota and its role in the pathogenesis of numerous cancers, our aim was to investigate how microbiota is affected by intestinal microenvironment and how microenvironment alterations may influence the response to immune checkpoint inhibitors (ICIs). In this context, we show how diet is emerging as a fundamental determinant of microbiota's community structure and function. Particularly, we describe the role of certain dietary factors, as well as the use of probiotics, prebiotics, postbiotics, and antibiotics in modifying the human microbiota. The modulation of gut microbiota may be a secret weapon to potentiate the efficacy of immunotherapies. In addition, this review sheds new light on the possibility of administering fecal microbiota transplantation to modulate the gut microbiota in cancer treatment. These concepts and how these findings can be translated into the therapeutic response to cancer immunotherapies will be presented.

摘要

人类微生物组及其与人体的功能相互作用最近重新成为科学界关注的焦点。鉴于更先进和日益精确的基因组测序技术、生物信息学和培养组学的广泛应用,我们现在拥有了非凡的能力来研究生活在人体内的微生物。最近的大多数研究仅关注肠道微生物群与另一个因素之间的相互作用。考虑到肠道微生物群的复杂性及其在许多癌症发病机制中的作用,我们的目的是研究微生物群如何受肠道微环境的影响,以及微环境的改变如何影响对免疫检查点抑制剂(ICIs)的反应。在这种情况下,我们展示了饮食如何成为影响微生物群落结构和功能的基本决定因素。特别是,我们描述了某些饮食因素的作用,以及益生菌、益生元、后生元和抗生素在改变人类微生物群中的作用。调节肠道微生物群可能是增强免疫疗法疗效的秘密武器。此外,本综述还揭示了通过粪便微生物移植来调节肠道微生物群以治疗癌症的可能性。这些概念以及如何将这些发现转化为癌症免疫疗法的治疗反应将被提出。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c56/8417795/e48139751492/fimmu-12-704942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c56/8417795/2802e2617cdb/fimmu-12-704942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c56/8417795/6fb484a26446/fimmu-12-704942-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c56/8417795/e48139751492/fimmu-12-704942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c56/8417795/2802e2617cdb/fimmu-12-704942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c56/8417795/6fb484a26446/fimmu-12-704942-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c56/8417795/e48139751492/fimmu-12-704942-g003.jpg

相似文献

1
The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?实体瘤中免疫检查点抑制剂耐药的挑战:微生物组及其多样性能否成为我们的秘密武器?
Front Immunol. 2021 Aug 20;12:704942. doi: 10.3389/fimmu.2021.704942. eCollection 2021.
2
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.调控肠道菌群以增强免疫检查点抑制剂的治疗效果。
Front Immunol. 2021 Jun 29;12:669150. doi: 10.3389/fimmu.2021.669150. eCollection 2021.
3
The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.肠道微生物群在克服癌症患者对检查点抑制剂耐药中的作用:机制和挑战。
Int J Mol Sci. 2021 Jul 27;22(15):8036. doi: 10.3390/ijms22158036.
4
The role of the gut microbiota in tumor, immunity, and immunotherapy.肠道微生物群在肿瘤、免疫和免疫治疗中的作用。
Front Immunol. 2024 Jun 5;15:1410928. doi: 10.3389/fimmu.2024.1410928. eCollection 2024.
5
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.调节肠道菌群以克服癌症免疫治疗中免疫检查点阻断的耐药性。
Curr Opin Pharmacol. 2020 Oct;54:1-10. doi: 10.1016/j.coph.2020.06.004. Epub 2020 Jun 30.
6
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.肠道微生物组在癌症免疫治疗中的调节作用:免疫检查点抑制剂阻断的新范例。
Cancer Med. 2021 Feb;10(3):1141-1154. doi: 10.1002/cam4.3694. Epub 2020 Dec 25.
7
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.癌症中新的生物学三角:肠道微生物群、免疫检查点抑制剂和抗生素。
Clin Transl Oncol. 2021 Dec;23(12):2415-2430. doi: 10.1007/s12094-021-02659-w. Epub 2021 Jun 14.
8
Complex interactions between the microbiome and cancer immune therapy.微生物组与癌症免疫治疗的复杂相互作用。
Crit Rev Clin Lab Sci. 2019 Dec;56(8):567-585. doi: 10.1080/10408363.2019.1660303. Epub 2019 Sep 17.
9
Gut microbiome in modulating immune checkpoint inhibitors.肠道微生物组在调节免疫检查点抑制剂中的作用。
EBioMedicine. 2022 Aug;82:104163. doi: 10.1016/j.ebiom.2022.104163. Epub 2022 Jul 15.
10
Gut microbiota and immunotherapy of renal cell carcinoma.肠道微生物群与肾细胞癌的免疫治疗。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2268982. doi: 10.1080/21645515.2023.2268982. Epub 2023 Nov 13.

引用本文的文献

1
Gut microbiota in colorectal cancer: a review of its influence on tumor immune surveillance and therapeutic response.结直肠癌中的肠道微生物群:对肿瘤免疫监视和治疗反应影响的综述
Front Oncol. 2025 Mar 5;15:1557959. doi: 10.3389/fonc.2025.1557959. eCollection 2025.
2
The Use of Coffee Cherry Pulp Extract as an Alternative to an Antibiotic Growth Promoter in Broiler Diets.咖啡樱桃果肉提取物作为肉鸡日粮中抗生素生长促进剂替代品的应用。
Animals (Basel). 2025 Jan 16;15(2):244. doi: 10.3390/ani15020244.
3
A Comprehensive Overview of Postbiotics with a Special Focus on Discovery Techniques and Clinical Applications.

本文引用的文献

1
New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries.癌症-微生物组-免疫轴的新见解:解码十年的发现。
Front Immunol. 2021 Feb 23;12:622064. doi: 10.3389/fimmu.2021.622064. eCollection 2021.
2
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.粪便微生物移植可促进免疫治疗耐药性黑色素瘤患者的应答。
Science. 2021 Feb 5;371(6529):602-609. doi: 10.1126/science.abb5920. Epub 2020 Dec 10.
3
The gut microbiota is associated with immune cell dynamics in humans.
后生元的全面概述:特别关注发现技术与临床应用
Foods. 2024 Sep 17;13(18):2937. doi: 10.3390/foods13182937.
4
The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.肠道微生物群在转移性肾细胞癌免疫调节中的作用。
Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122714. doi: 10.1177/17588359221122714. eCollection 2022.
5
An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.质子泵抑制剂的使用与晚期实体癌中免疫检查点抑制剂临床疗效之间相关性的最新研究:一项系统评价和荟萃分析
Front Oncol. 2022 Feb 24;12:753234. doi: 10.3389/fonc.2022.753234. eCollection 2022.
肠道微生物群与人类免疫细胞动力学有关。
Nature. 2020 Dec;588(7837):303-307. doi: 10.1038/s41586-020-2971-8. Epub 2020 Nov 25.
4
Analyses of Potential Driver and Passenger Bacteria in Human Colorectal Cancer.人类结直肠癌中潜在驱动菌和乘客菌的分析
Cancer Manag Res. 2020 Nov 12;12:11553-11561. doi: 10.2147/CMAR.S275316. eCollection 2020.
5
Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy.肠道微生物群:调节免疫治疗和化疗疗效的新角色。
Cancer Drug Resist. 2020;3(3):356-370. doi: 10.20517/cdr.2020.04. Epub 2020 Mar 21.
6
Emerging role of microbiota in immunomodulation and cancer immunotherapy.微生物群在免疫调节和癌症免疫治疗中的新兴作用。
Semin Cancer Biol. 2021 May;70:37-52. doi: 10.1016/j.semcancer.2020.06.008. Epub 2020 Jun 21.
7
Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer.肠道微生物群调节:预防和治疗结直肠癌的新策略。
Oncogene. 2020 Jun;39(26):4925-4943. doi: 10.1038/s41388-020-1341-1. Epub 2020 Jun 8.
8
Alterations of the Predominant Fecal Microbiota and Disruption of the Gut Mucosal Barrier in Patients with Early-Stage Colorectal Cancer.早期结直肠癌患者主要粪便微生物群的改变和肠道黏膜屏障的破坏。
Biomed Res Int. 2020 Mar 19;2020:2948282. doi: 10.1155/2020/2948282. eCollection 2020.
9
Microbiome and Breast Cancer: New Role for an Ancient Population.微生物群与乳腺癌:古老群体的新作用。
Front Oncol. 2020 Feb 12;10:120. doi: 10.3389/fonc.2020.00120. eCollection 2020.
10
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.抗生素和质子泵抑制剂治疗的非小细胞肺癌患者的化疗和阿特珠单抗疗效:OAK 和 POPLAR 试验的汇总事后分析。
Ann Oncol. 2020 Apr;31(4):525-531. doi: 10.1016/j.annonc.2020.01.006. Epub 2020 Jan 16.